Meeting
2023 ASCO Annual Meeting
Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
Authors
Zhongjie Chen
Tianjin Medical University Cancer Hospital & Institute, Tianjin, China
Zhongjie Chen , Bo Yan , Liming Xu , Xin Huang , Meng Li , Jun Wang , Li Zhu , Zhiyong Yuan , Ping Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT04884906
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5542)
DOI
10.1200/JCO.2023.41.16_suppl.5542
Abstract #
5542
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
First Author: Hu Liang
Poster
2024 ASCO Breakthrough
Efficacy and safety analysis on the combination of camrelizumab with nab-paclitaxel and cisplatin-based chemotherapy in first-line treatment of advanced or metastatic esophageal squamous cell carcinoma.
First Author: Xiaofeng Cong
Poster
2024 ASCO Annual Meeting
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Huiyan Luo
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu